Immunome Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
Portfolio Pulse from
Immunome, Inc. has successfully closed an upsized public offering, raising significant capital through the sale of 22,258,064 shares, including additional shares purchased by underwriters. The offering was priced at $7.75 per share.
January 31, 2025 | 9:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Immunome has completed a successful public offering, raising capital by selling 22,258,064 shares at $7.75 each. This includes the full exercise of the underwriters' option to purchase additional shares.
The successful closing of the public offering and the full exercise of the underwriters' option indicate strong demand and confidence in Immunome's stock. This capital raise is likely to support the company's growth and development of cancer therapies, positively impacting the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100